November 2, 2026
Alnylam shares fell 25 percent even after the company beat quarterly earnings, as the market questioned the drugmaker's growth outlook.
What happened
The stock dropped 4.5 percent on the day, a move larger than 93 percent of its daily changes over the past three years. The decline erased roughly 500 billion dollars in market value. It came despite a third quarter earnings beat, with investors instead focusing on demand growth concerns.
Why it matters
When a stock falls sharply on a profit beat, the market is sending a clear signal that future revenues matter more than past results. The selloff punishes shareholders and raises Alnylam's cost of raising capital. The move tells every biotech executive that valuation can crack even when you deliver good numbers if the demand story weakens.
The case against
A single day's move, even a large one, can overreact. Alnylam beat earnings, meaning its actual business performed better than expected. The pipeline supporting future demand may be stronger than the selloff implies, and the drop could prove to be a short term correction driven by crowded positioning rather than a real deterioration.
What settles it
Whether Alnylam's next product approvals or prescription data confirm that patient demand is actually slowing.